ValJLoweMD

Nuclear Medicine • Rochester, MN

Professor, Radiology, Mayo Medical School

Join to view full profile

Are you Dr. Lowe?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 55 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
200 1st St Sw
Rochester, MN 55905
Phone+1 507-284-2511

Summary

Dr. Val Lowe, MD is a board certified nuclear medicine physician in Rochester, Minnesota. He is currently licensed to practice medicine in Minnesota, Florida, and Georgia. He is affiliated with Mayo Clinic Hospital - Rochester and is a Professor at Mayo Medical School.

Education & Training

Duke University HospitalResidency, Nuclear Medicine, 1991 - 1994
LDS HospitalResidency, Internal Medicine, 1988 - 1991
McGill University Faculty of MedicineClass of 1988

Certifications & Licensure

FL State Medical License 2013 - 2027
AZ State Medical License 2001 - 2026
UT State Medical License 1989 - 2026
MN State Medical License 1999 - 2025
WI State Medical License 2013 - 2025
IA State Medical License 2013 - 2023
GA State Medical License 2013 - 2016
NC State Medical License 1991 - 1999
American Board of Nuclear Medicine Nuclear Medicine
Join now to see all

Clinical Trials

Everolimus in Treating Patients With Stage IV Melanoma Start of enrollment: 2005 Apr 01
Completed
Phase 2
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
Withdrawn
Phase 2
Imaging of Brain Amyloid Plaques in the Aging Population Start of enrollment: 2008 Apr 01
Enrolling by invitation
Phase 4
FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer Start of enrollment: 2010 Apr 01
Active, not recruiting
Not Applicable
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET) Start of enrollment: 2012 Jul 01
Completed
Phase 2
Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma Start of enrollment: 2003 Aug 01
Completed
Phase 2
Effects of Aging and Aerobic Exercise Training on Brain Glucose Metabolism Start of enrollment: 2012 Oct 01
Completed
Not Applicable
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer Start of enrollment: 2019 Jan 03
Active, not recruiting
Early Phase 1
Gallium-68 PSMA-11 PET/CT for the Diagnosis of Biochemically Recurrent Prostate Cancer
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia Start of enrollment: 2021 Mar 30
Enrolling by invitation
Phase 2
Join now to see all

Publications & Presentations

PubMed

Cardiorespiratory dynamics in the brain: Review on the significance of cardiovascular and respiratory correlates in functional MRI signal.
Mahathi Kandimalla, Seokbeen Lim, Jay Thakkar, Sannidhi Dewan, Daehun Kang
Neuroimage. 2025-02-01
Identifying gait differences between Alzheimer's disease and dementia with Lewy bodies and their associations with regional amyloid deposition.
Salma Elasfar, Hajr Hameed, Bradley F Boeve, Julie A Fields, Clifford R Jack Jr
Alzheimer's & Dementia. 2025-01-27
Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum.
Daniel Ferreira, Scott A Przybelski, Timothy G Lesnick, Patricia Diaz-Galvan, Christopher G Schwarz
JAMA Neurology. 2025-01-13

Press Mentions

Meet Mukesh Pandey, Ph.D. – Developing a New Drug to Detect Prostate Cancer in Its Earliest StagesSeptember 23rd, 2019
Surgical Planning for Head and Neck Cancer Benefits from FDG-PET/CTAugust 7th, 2019
Game Changers: Five Innovative Tests for Cancer DetectionSeptember 21st, 2017
Join now to see all